Pliant Therapeutics, Inc.
700 Saginaw Drive
Suite 150
Redwood City
California
94063
United States
80 articles with Pliant Therapeutics, Inc.
-
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
8/8/2022
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported second quarter 2022 financial results.
-
Pliant Therapeutics to Participate in BTIG Biotechnology Conference
8/2/2022
Pliant Therapeutics, Inc. today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, will participate in a panel discussion at the BTIG Biotechnology Conference 2022.
-
FDA Weekly Review looks at the FDA's actions related to drug approvals, IND approvals, designations and more. Here’s a look at what happened this week.
-
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Primary Sclerosing Cholangitis
7/21/2022
Pliant Therapeutics (NASDAQ: PLRX) announced today that PLN-74809, its oral, dual-selective α v ß 6 / α v ß 1 integrin inhibitor, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the potential treatment of primary sclerosing cholangitis (PSC).
-
Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
7/15/2022
Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced the closing of its previously announced upsized underwritten public offering of 12,432,432 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 1,621,621 additional shares, at a price to the public of $18.50 per share.
-
Pliant Therapeutics Announces Pricing of Upsized $200.0 Million Public Offering
7/12/2022
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the pricing of an upsized underwritten public offering of 10,810,811 shares of its common stock at a price to the public of $18.50 per share.
-
Annexon and Pliant Therapeutics both made efforts to secure additional financing to support their R&D endeavors.
-
Pliant Therapeutics Announces Proposed Public Offering of Common Stock - July 11, 2022
7/11/2022
Pliant Therapeutics, Inc., a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, announced that it has commenced an underwritten public offering of $150.0 million of its common stock.
-
Pliant Therapeutics Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis
7/10/2022
Pliant Therapeutics, Inc., announced positive data from INTEGRIS-IPF, a multinational, randomized, double-blind, placebo-controlled Phase 2a clinical trial of PLN-74809 in patients with idiopathic pulmonary fibrosis.
-
Pliant Therapeutics Announces Presentations at the International Liver Congress™ 2022 Highlighting Preclinical and Clinical Data in Support of the INTEGRIS-PSC Phase 2a Clinical Trial
6/24/2022
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the presentation of two scientific posters at the International Liver Congress™ (ILC) 2022 of the European Association for the Study of the Liver (EASL), taking place June 22-26, 2022, in London, United Kingdom.
-
Pliant Therapeutics Presents Preclinical Data Highlighting A Novel Approach for the Treatment of Muscular Dystrophies
6/22/2022
Pliant Therapeutics, Inc. (Nasdaq: PLRX) presented new preclinical data highlighting the potential of PLN-101325, an α 7 β 1 integrin activating antibody for the treatment of muscular dystrophies, including Duchenne Muscular Dystrophy (DMD).
-
Pliant Therapeutics Announces Advancement of Integrin Target in Fibrosis Under Strategic Collaboration
6/16/2022
Pliant Therapeutics, Inc. today announced the dvancement of a fibrosis-directed integrin target into development as part of the Company’s 2019 research and development collaboration with Novartis.
-
Pliant Therapeutics Announces Presentations at the International Liver Congress™ 2022
6/15/2022
Pliant Therapeutics, Inc. announced that the Company will present two scientific posters at the International Liver Congress™ 2022 of the European Association for the Study of the Liver, taking place June 22-26, 2022, in London, United Kingdom.
-
Pliant Therapeutics to Participate in Upcoming Investor Conferences - May 11, 2022
5/11/2022
Pliant Therapeutics, Inc. announced that Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer, will participate in the following May investor conferences.
-
Pliant Therapeutics Enters into $100 million Loan Facility Agreement with Oxford Finance to Support Ongoing Development of PLN-74809
5/5/2022
Pliant Therapeutics, Inc. announced it has entered into a loan facility agreement with Oxford Finance LLC for up to $100 million of non-dilutive financing.
-
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Idiopathic Pulmonary Fibrosis
5/3/2022
Pliant Therapeutics (NASDAQ: PLRX) announced today that PLN-74809 has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the potential treatment of idiopathic pulmonary fibrosis (IPF).
-
Pliant Therapeutics Announces Multiple Presentations at the 2022 American Thoracic Society International Conference
5/2/2022
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that the Company will present five scientific posters at the upcoming 2022 American Thoracic Society (ATS) International Conference.
-
Pliant Therapeutics to Participate in Needham Healthcare Conference
4/5/2022
Pliant Therapeutics, Inc. announced that Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer, will participate in a fireside chat as part of the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022, at 2:15 p.m. ET.
-
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
2/28/2022
Pliant Therapeutics, Inc., a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, provided a corporate update and reported fourth quarter and full year 2021 financial results.
-
Pliant Therapeutics Announces Positive Data from Expanded Phase 1b BAL Trial of PLN-74809 Demonstrated Suppression of TGF-β Signaling in Healthy Volunteers
2/28/2022
Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced positive data from its expanded PLN-74809 Phase 1b proof-of-mechanism trial.